No Data
No Data
HSBC Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $20
Express News | Teva : HSBC Cuts Target Price to $20 From $24
Headache For MOH With Trump's Flip-Flop On Pharma Tariff
Express News | 'FDA Commissioner Says 'No Plans' To Pull Abortion Pill Mifepristone' - Financial Times
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Bausch Health: U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, Teva Against Norwich